Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy

Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy

Autor Dall'Oglio, Marcos Francisco Autor UNIFESP Google Scholar
Crippa, Alexandre Autor UNIFESP Google Scholar
Antunes, Alberto A. Autor UNIFESP Google Scholar
Nesrallah, Luciano J. Autor UNIFESP Google Scholar
Leite, Kátia Ramos Moreira Autor UNIFESP Google Scholar
Srougi, Miguel Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo INTRODUCTION: The unpredictability of prostate cancer has become a daily challenge for the urologist, with different strategies being required to manage these cases. In this study, we report on the perspectives for curing prostate cancer in males undergoing radical prostatectomy with Gleason score of 2-6 on prostate biopsy in relation to pre-operative PSA levels. MATERIALS AND METHODS: From 1991 - 2000, we selected 440 individuals whose pathological diagnosis revealed a Gleason score of 2-6 upon prostate biopsy and who subsequently underwent retro-pubic radical prostatectomy due to localized prostate cancer. The clinical stage identified in the group under study was T1c: 206 (46.8%); T2a: 122 (27.7%); T2b: 93 (21.1%); T2c: 17 (3.9%); T3a: 2 (0.5%). Following surgery, we constructed a biochemical recurrence-free survival curve according to pre-operative PSA levels between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL, with a median follow-up of 5 years. RESULTS: Following radical prostatectomy, the pathological stage was confirmed as pT2a: 137 (31.1%); T2b: 118 (26.8%); T2c: 85 (19.3%); T3a: 67 (15.2%); T3b: 6 (1.4%); T3c: 22 (5%). The biochemical recurrence-free survival, according to PSA values between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL, was 86.6%, 62.7%, 39.8% and 24.8% respectively. CONCLUSION: Better chances for curing low-grade prostate cancer occur in individuals with normal PSA for whom a biopsy is not usually recommended.
Assunto prostatic neoplasms
prostate-specific antigen
Idioma Inglês
Data 2005-06-01
Publicado em International braz j urol. Sociedade Brasileira de Urologia, v. 31, n. 3, p. 222-227, 2005.
ISSN 1677-5538 (Sherpa/Romeo)
Editor Sociedade Brasileira de Urologia
Extensão 222-227
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1677-55382005000300005 (estatísticas na SciELO)

Mostrar registro completo

Arquivos deste item

Nome: S1677-55382005000300005.pdf
Tamanho: 86.15Kb
Formato: PDF

Este item aparece na(s) seguinte(s) coleção(s)